IMCC - Earnings announcements

TORONTO and GLIL YAM, Israel, May 13, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated. For the three months ended March 31, 2026, the Company recorded revenues of $8.7 million, gross profit of $1.4 million, operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The Company also continued to advance its co

TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights:  Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating

IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel, Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated. Q2 2025 Financial Highlights   14% Revenue decrease vs. Q2 2024 of $12.7M vs. $14.8M  306% Gross profit increase vs.

TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (NASDAQ:IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company's focus is to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company lever

IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated. IMC also announces the intention to complete a non-brokered private placement of secured debentures. Q1 2025 Financial Highlights Net profit of $175K94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gr

TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage

TORONTO and GLIL YAM, Israel, March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a

IMC pairs a +12% increase in revenue with a -16% decrease in the total operating expenses, building a solid foundation to deliver in 2025. TORONTO and GLIL YAM, Israel, Nov. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended September 30, 2023, unless otherwise stated. Q3 2024 Financial Highlights +12% increase in Revenue to $13.9M vs. $12.4M in Q3, 2023. Adjusting for the revocation of the Oranim deal, increases the revenue to +51% or $4.7M vs

IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023 TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated. Q2 2024 Financial Highlights 12% Revenue increase to $14.8M vs. $13.2M in Q2 2023  129% increase in IMC Germany sales vs. Q2 2023 to $3.5M. IMC Germany sales now make up 24% of the entire Company r

TORONTO and GLIL YAM, Israel, Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel-Hamas war. TORONTO and GLIL YAM, Israel, May 8, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated. Q1 2024 Financial Highlights 13% Revenue increase vs. Q4 2023 of $12.1M vs. $10.7M and 4% decrease vs. Q1 2023 of $12.5M  125% Gross profit increase vs. Q4 2023 of $1.8M vs. $0.8 and 39% Gross profit decrea

TORONTO and GLIL YAM, Israel, May 1, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2024 ended March 31, 2024, on Wednesday, May 8, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call

TORONTO and GLIL YAM, Israel, March 28, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial and operational results for the year ended December 31, 2023, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company's full set of consolidated audited financial statements for the years ended December 31, 2023 and 2022 (the "Annual Financial Statements") and accompanying management's discussion and analysis (the "Annual MD&A") can be accessed by visiting the Company's website at https://investors.imcannabis.com/, and its profile pages o

TORONTO and GLIL YAM, Israel, March 20, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2023 ended December 31, 2023, on Thursday, March 28, 2024 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live,

IMC remains singularly focused on accelerating its path to profitability through active cost management and margin improvement while maintaining sales. TORONTO, and GLIL YAM, Israel, Nov. 13, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2023. All amounts are reported in Canadian dollars and compared to the quarter ended September 30, 2022, unless otherwise stated. The full set of unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2023 (the "Q3 FS"), and the accompan

IMC remains singularly focused on accelerating the path to profitability through active cost management and margin improvement while maintaining sales. TORONTO and GLIL YAM, Israel, Aug. 14, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2023. All amounts are reported in Canadian dollars and compared to Q2 2022 unless otherwise stated.      The full set of consolidated financial statements for the three and six months ended June 30, 2023 (the "Q2 FS"), and the accompanying management's discussion and analysis (the "Q2 MD&A"), can be

TORONTO and GLIL YAM, Israel, Aug. 8, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call wi

TORONTO and GLIL YAM, Israel, Aug. 8, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call wi

IMC leans further into its strategy, continuing to focus on the Israeli and German markets with a primary goal of sustainably increasing revenue in each of these core markets, while accelerating its path to profitability through active cost management and margin improvement. TORONTO and GLIL YAM, Israel, May 15, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2023. All amounts are reported in Canadian dollars and compared to Q1 2022 unless otherwise stated. Q1 2023 Financial Highlights  46% increase in gross profit and 35% compared

TORONTO and GLIL YAM, Israel, May 8, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter ended March 31, 2023, on Monday, May 15, 2023 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call will b

Company to continue its focus on the Israeli and German markets with a primary goal of sustainably increasing revenue in each of these core markets and accelerating path to profitability, while actively managing costs and margins TORONTO, and GLIL YAM, Israel, March 29, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, today announced its financial results for the fourth quarter and full year ended December 31, 2022. All amounts are reported in Canadian dollars unless otherwise stated. Management Commentary "The fourth quarter marked another pivotal moment on our trajectory to growth and profitability," said O

TORONTO and GLIL YAM, Israel, March 15, 2023 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022 on Wednesday, March 29, 2023, before the market opens. The Company will host a zoom web conference call on the same day at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call will be

Company to refocus resources and efforts on the Israeli and German markets; Commences exit of the Canadian market TORONTO and GLIL YAM, Israel, Nov. 14, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE:IMCC) (NASDAQ:IMCC), a leading medical cannabis company, provided financial results for its third quarter ended September 30, 2022. All amounts are reported in Canadian dollars unless otherwise stated.   Q3 2022 Highlights Revenues for Q3 2022 were $14.2 million, compared to $8.0 million on Q3 2021, an increase of 78%, representing a 12% sequential organic growth.Gross profit, before fair value adjustments, for Q3 2022 was $2.8 million, compared to $2.0 mil

TORONTO and GLIL YAM, Israel, Nov. 1, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022 before market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us l

Gross margin of 24%, which is expected to increase with further asset integration, product availability, and operational improvements Approximately $6.5 million per year in expected cash cost savings from streamlining operations in Canada and closure of Israeli cultivation farm TORONTO and GLIL YAM, Israel, Aug. 15, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, provided financial results for its second quarter ended June 30, 2022. All amounts are reported in Canadian dollars unless otherwise stated. Q2 2022 Highlights Reve

TORONTO and GLIL YAM, Israel, Aug. 4, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and financial results for the second quarter ended June 30, 2022, on Monday, August 15, 2022 before market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a

Gross Profit Increased 37% from Q1 2021 as Operational Efficiencies from Integration Take Hold; Company Expects to Achieve Positive Adjusted EBITDA in Q2 2022 TORONTO and GLIL YAM, Israel, May 12, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, provided financial results for the three months ended March 31, 2022. All amounts are reported in Canadian dollars unless otherwise stated. Q1 2022 Highlights  Revenues increased 169% year-over-year to $23.6 millionGross profit, before fair value adjustments, was $6.4 million, represent

TORONTO, Canada and GLIL YAM, Israel, May 5, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and financial results for the first quarter ended March 31, 2022 after market close on Thursday, May 12, 2022.     Management will host a conference call to discuss the results, followed by a question-and-answer session from participants. To participate, please use the following information: Q1 2022 Conference Call Date: Thursday, May 12, 2022 Time: 5:00 p.m. Eastern time U.S./Canada Dial-in: 1-844-825-9789 Israel Dial

- Fiscal Year 2021 revenues increased 242% year-over-year to a record of over $54 million - Q4 2021 revenues increased 309% year-over-year and 39% compared to Q3 2021 - Sequential revenue growth and gross margin improvement expected in Q1 2022 TORONTO, and GLIL YAM, Israel, March 31, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company", "IM Cannabis", or "IMC") (CSE:IMCC) (NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, provided financial results for the three months and fiscal year ended December 31, 2021. All amounts are reported in Canadian dollars unless otherwise stated. Q4 and Full Year 2021 Financial Summ

TORONTO and GLIL YAM, Israel, March 29, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC, NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, has rescheduled the release of its operational and financial results for the fourth quarter and full year ended December 31, 2021, to before market open on Thursday, March 31, 2022.     Management will host a conference call to discuss the results, followed by a question-and-answer session from participants. To participate, please use the following information: Q4 and Full Year 2021 Conference Call Date: Thursday, March 31, 2022Time: 9:00 a.m. East

TORONTO and GLIL YAM, Israel, March 23, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC, NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and financial results for the fourth quarter and full year ended December 31, 2021 before market open on Wednesday, March 30, 2022.     Management will host a conference call to discuss the results, followed by a question-and-answer session from participants. To participate, please use the following information: Q4 and Full Year 2021 Conference Call Date: Wednesday, March 30, 2022 Time: 9:00 a.m. Eastern time (6:00 a.m. Paci

TORONTO, ON and GLIL YAM, Israel, Feb. 8, 2022 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (CSE:IMCC) ("IM Cannabis" or the "Company"), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, has engaged international investor relations specialists MZ Group ("MZ") to lead the Company's strategic investor relations and financial communications program across all key markets. MZ will work closely with IM Cannabis management to develop and implement a comprehensive capital markets strategy designed to increase the Company'

KELOWNA, BC, Oct. 13, 2021 /CNW/ - Avant Brands Inc (TSX:AVNT) (OTCQX:AVTBF) (FRA: 1BUP) ("Avant" or the "Company"), a leading producer of high quality, handcrafted cannabis products, is pleased to announce its financial results for the third quarter of fiscal 2021 ended August 31, 2021 ("Q3 2021"). "We are excited to have posted two consecutive quarters of record revenues," said Norton Singhavon, Founder and CEO of Avant. "The Company has achieved positive momentum across three distinct channels: recreational, medical and export. In addition, the recent licensing of our 3PL

Vancouver, British Columbia--(Newsfile Corp. - April 30, 2021) - MYM Nutraceuticals Inc., (CSE:MYM) (OTCQB:MYMMF) ("MYM" or the "Company") today announced its financial results for the three-month period ending February 28, 2021 ("Q3 2021"). The Company's Financial Statements and Management Discussion & Analysis ("MD&A") are available on sedar.com. Key Highlights for Q3 2021Gross revenue of $4.4 million, an increase of 8% from the prior quarterPositive EBITDA of $212,628Expanded distribution to three new markets: Yukon, Nunavut, and OntarioSubsequent to Q3 2021, announced a definitive agreement to merge with IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) ("IMCC") (the "Transaction") with over 4